UB Paderborn / Katalog / Suche / in CDI

Retrospective Analysis of Topoisomerase IIa Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative Group

Journal of clinical oncology, 2005-10, Vol.23 (30), p.7483-7490

2005

Link zum Volltext

Verfügbarkeit prüfen

HER2, TOP2A, and TIMP-1 and Responsiveness to Adjuvant Anthracycline-Containing Chemotherapy in High-Risk Breast Cancer Patients

Journal of clinical oncology, 2010-02, Vol.28 (6), p.984-990

2010

Link zum Volltext

Verfügbarkeit prüfen

Value of Epidermal Growth Factor Receptor, HER2, p53, and Steroid Receptors in Predicting the Efficacy of Tamoxifen in High-Risk Postmenopausal Breast Cancer Patients

Journal of clinical oncology, 2001-07, Vol.19 (14), p.3376-3384

2001

Link zum Volltext

Verfügbarkeit prüfen

Divergent estrogen receptor‐positive and ‐negative breast cancer trends and etiologic heterogeneity in Denmark

International journal of cancer, 2013-11, Vol.133 (9), p.2201-2206

2013

Link zum Volltext

Verfügbarkeit prüfen

Population-Based Study of Peritumoral Lymphovascular Invasion and Outcome Among Patients With Operable Breast Cancer

JNCI : Journal of the National Cancer Institute, 2009-05, Vol.101 (10), p.729-735

2009

Link zum Volltext

Verfügbarkeit prüfen

Mortality Rates Among Early-Stage Hormone Receptor-Positive Breast Cancer Patients: A Population-Based Cohort Study in Denmark

JNCI : Journal of the National Cancer Institute, 2011-09, Vol.103 (18), p.1363-1372

2011

Link zum Volltext

Verfügbarkeit prüfen

Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer

Breast cancer research and treatment, 2011-06, Vol.127 (2), p.345-355

2011

Link zum Volltext

Verfügbarkeit prüfen

Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays

Journal of clinical pathology, 2007-04, Vol.60 (4), p.397-404

2007

Link zum Volltext

Verfügbarkeit prüfen

One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer

European journal of cancer (1990), 2013-09, Vol.49 (14), p.2986-2994

2013

Link zum Volltext

Verfügbarkeit prüfen

High Concordance Between Two Companion Diagnostics Tests: A Concordance Study Between the HercepTest and the HER2 FISH pharmDx Kit

American journal of clinical pathology, 2011-07, Vol.136 (1), p.145-151

2011

Link zum Volltext

Verfügbarkeit prüfen

Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients ( n = 647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study

European journal of cancer (1990), 2009-09, Vol.45 (14), p.2528-2536

2009

Link zum Volltext

Verfügbarkeit prüfen

The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors

Pharmacogenetics (London), 2002-08, Vol.12 (6), p.473-478

2002

Link zum Volltext

Verfügbarkeit prüfen

Fluvoxamine is a potent inhibitor of cytochrome P4501A2

Biochemical pharmacology, 1993-03, Vol.45 (6), p.1211-1214

1993

Link zum Volltext

Verfügbarkeit prüfen

Argyrophilic cells in 202 human mucinous breast carcinomas: relation to histopathologic and clinical factors

American journal of clinical pathology, 1985-12, Vol.84 (6), p.737-740

1985

Link zum Volltext

Verfügbarkeit prüfen

BENEFICIAL EFFECT OF ADJUVANT TAMOXIFEN THERAPY IN PRIMARY BREAST CANCER PATIENTS WITH HIGH OESTROGEN RECEPTOR VALUES

The Lancet (British edition), 1985-01, Vol.325 (8419), p.16-19

1985

Link zum Volltext

Verfügbarkeit prüfen

The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid-binding assays

European journal of cancer & clinical oncology, 1990-04, Vol.26 (4), p.442-449

1990

Link zum Volltext

Verfügbarkeit prüfen

Effects of intravenous fluid restriction on postoperative complications: Comparison of two perioperative fluid regimens a randomized assessor-blinded multicenter trial

Annals of surgery, 2003-11, Vol.238 (5), p.641-648

2003

Link zum Volltext

Verfügbarkeit prüfen

Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial

The Lancet (British edition), 1999-05, Vol.353 (9165), p.1641-1648

1999

Link zum Volltext

Verfügbarkeit prüfen

Metabolite profiles of degarelix, a new gonadotropin-releasing hormone receptor antagonist, in rat, dog, and monkey

Drug metabolism and disposition, 2011-10, Vol.39 (10), p.1895

2011

Link zum Volltext

Verfügbarkeit prüfen

Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?

Therapeutic drug monitoring, 2000-04, Vol.22 (2), p.143-154

2000

Link zum Volltext

Verfügbarkeit prüfen

Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients with insulin dependent diabetes

BMJ (Online), 1996-04, Vol.312 (7035), p.871

International edition, 1996

Link zum Volltext

Verfügbarkeit prüfen

Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide

Clinical pharmacology and therapeutics, 1997-09, Vol.62 (3), p.279-286

1997

Link zum Volltext

Verfügbarkeit prüfen

The Nottingham prognostic index applied to 9,149 patients from the studies of the danish breast cancer cooperative group (DBCG)

Breast cancer research and treatment, 1994, Vol.32 (3), p.281-290

1994

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic interaction studies of atosiban with labetalol or betamethasone in healthy female volunteers

BJOG : an international journal of obstetrics and gynaecology, 2005-11, Vol.112 (11), p.1492-1499

2005

Link zum Volltext

Verfügbarkeit prüfen

Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans

Therapeutic drug monitoring, 1996-06, Vol.18 (3), p.254-262

1996

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Retrospective Analysis of Topoisomerase IIa Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative Group

HER2, TOP2A, and TIMP-1 and Responsiveness to Adjuvant Anthracycline-Containing Chemotherapy in High-Risk Breast Cancer Patients

Value of Epidermal Growth Factor Receptor, HER2, p53, and Steroid Receptors in Predicting the Efficacy of Tamoxifen in High-Risk Postmenopausal Breast Cancer Patients

Divergent estrogen receptor‐positive and ‐negative breast cancer trends and etiologic heterogeneity in Denmark

Population-Based Study of Peritumoral Lymphovascular Invasion and Outcome Among Patients With Operable Breast Cancer

Mortality Rates Among Early-Stage Hormone Receptor-Positive Breast Cancer Patients: A Population-Based Cohort Study in Denmark

Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer

Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays

One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer

High Concordance Between Two Companion Diagnostics Tests: A Concordance Study Between the HercepTest and the HER2 FISH pharmDx Kit

Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients ( n = 647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study

The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors

Fluvoxamine is a potent inhibitor of cytochrome P4501A2

Argyrophilic cells in 202 human mucinous breast carcinomas: relation to histopathologic and clinical factors

BENEFICIAL EFFECT OF ADJUVANT TAMOXIFEN THERAPY IN PRIMARY BREAST CANCER PATIENTS WITH HIGH OESTROGEN RECEPTOR VALUES

The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid-binding assays

Effects of intravenous fluid restriction on postoperative complications: Comparison of two perioperative fluid regimens a randomized assessor-blinded multicenter trial

Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial

Metabolite profiles of degarelix, a new gonadotropin-releasing hormone receptor antagonist, in rat, dog, and monkey

Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?

Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients with insulin dependent diabetes

Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide

The Nottingham prognostic index applied to 9,149 patients from the studies of the danish breast cancer cooperative group (DBCG)

Pharmacokinetic interaction studies of atosiban with labetalol or betamethasone in healthy female volunteers

Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans

Aktive Filter

Suchergebnisse filtern